BENEDICT: primary prevention of microalbuminuria in hypertensive type 2 diabetes

Ruggenenti P. , Fassi A. , Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51.

Wild S. , Roglic G. , Green A. et al. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27: 1047-53.

Adler AI , Stevens RJ , Manley SE et al. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney International 2003;63:225-32.

The Royal College of General Practitioners Effective Clinical Practice Unit. Guideline entitled `Diabetic renal disease: prevention and early management.' 2002 Accessed at: http://www.nice.org.uk/page.aspx?o=39385

Marshall SM Review. Recent advances in diabetic nephropathy. Postgrad Med J 2004;80:624-33.

de Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int Suppl 2004;92:S2-S6.

Parving H-H. , Lehnert H. , Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.

Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:53-9.

Lewis EJ , Hunsicker LG , Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.

Continued on page 88

Continued from page 86

Brenner BM , Cooper ME , de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.

Bakris GL , Weir MR , De Quattro V. et al. Effects of ACE inhibitor/calcium channel antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1996;50:1641-50.

de Zeeuw D. , Remuzzi G. , Parving H-H. et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy . Circulation 2004;110:921-7.

Furtner M. , Kiechl S. , Mair A. et al. Urinary albumin excretion is independently associated with carotid and femoral atherosclerosis in the general population. Euro Heart J 2005;26:279-87.

Ravid M. , Brosh D. , Levi Z. et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. Annals Int Med 1998;128:982-8.

5. The EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-92.

Strippoli GFM , Craig M. , Deeks JJ et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828-31.

So WY , Ozaki R. , Chan NN et al. Effect of angiotensin-converting enzyme inhibition on survival in 3,773 Chinese type 2 diabetic patients. Hypertension 2004;44:294-9.

NICE. Inherited guideline H , 2002. Management of type 2 diabetes - management of blood pressure and blood lipids. Accessed at: http://www.nice.org.uk/page.aspx?o=38551